13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Transplantation from a symptomatic carrier sister restores host defenses but does not prevent colitis in NEMO deficiency.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          NF-κB essential modulator (NEMO) deficiency causes ectodermal dysplasia with immunodeficiency in males, while manifesting as incontinentia pigmenti in heterozygous females. We report a family with NEMO deficiency, in which a female carrier displayed skewed X-inactivation favoring the mutant NEMO allele associated with symptoms of Behçet's disease. Hematopoietic stem cell transplantation of an affected boy from this donor reconstituted an immune system with retained skewed X-inactivation. After transplantation no more severe infections occurred, indicating that an active wild-type NEMO allele in only 10% of immune cells restores host defense. Yet he developed inflammatory bowel disease (IBD). While gut infiltrating immune cells stained strongly for nuclear p65 indicating restored NEMO function, this was not the case in intestinal epithelial cells - in contrast to cells from conventional IBD patients. These results extend murine observations that epithelial NEMO-deficiency suffices to cause IBD. High anti-TNF doses controlled the intestinal inflammation and symptoms of Behçet's disease.

          Related collections

          Author and article information

          Journal
          Clin. Immunol.
          Clinical immunology (Orlando, Fla.)
          Elsevier BV
          1521-7035
          1521-6616
          Mar 2016
          : 164
          Affiliations
          [1 ] Center of Chronic Immunodeficiency, University Medical Center Freiburg, Germany; Center for Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Germany.
          [2 ] Institute for Transfusion Medicine, University of Ulm, Ulm, Germany; Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service, Ulm, Germany.
          [3 ] Department of Clinical Genetics and Genomics, Royal Brompton and Harefield NHS Foundation Trust, Imperial College London, UK.
          [4 ] CECAD Research Center, Institute for Genetics, University of Cologne, Cologne, Germany.
          [5 ] Center of Chronic Immunodeficiency, University Medical Center Freiburg, Germany.
          [6 ] Department of Pediatrics, and Translational Gastroenterology Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.
          [7 ] Center for Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Germany.
          [8 ] Center of Chronic Immunodeficiency, University Medical Center Freiburg, Germany; Institute for Transfusion Medicine, University of Ulm, Ulm, Germany; Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service, Ulm, Germany.
          [9 ] Center of Chronic Immunodeficiency, University Medical Center Freiburg, Germany; Center for Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Germany. Electronic address: jan.rohr@uniklinik-freiburg.de.
          Article
          S1521-6616(16)30010-9 EMS79054
          10.1016/j.clim.2016.01.010
          6101191
          26812624
          88b088bb-d7ea-4aef-8742-7fdb9a1e49a3
          Copyright © 2016 Elsevier Inc. All rights reserved.
          History

          Anti-TNF treatment,Behçet's disease,HSCT,IBD,IKBKG,NEMO deficiency,Skewed X-inactivation

          Comments

          Comment on this article